Abstract:Background A retrospective utilization study was performed to evaluate utilization patterns for enteral nutrition in a university teaching hospital. Methods Enteral nutrition was divided into three types according to the nitrogen source, ie, total protein type [Nutrison Fibre®, Fresubin Energy Fibre®, Fresubin®, Supportan® (a special immunonutrition for cancer patients or patients with increased demands for omega-3 fatty acids), Fresubin Diabetes® (a diabetes-specific formula), Ensure®]; short peptide type (Peptison®); and amino acid type (Vivonex®). A pharmacoeconomic analysis was done based on defined daily dose methodology. Results Among hospitalized patients taking enteral nutrition, 34.8% received enteral nutrition alone, 30% concomitantly received parenteral nutrition, and 35.2% received enteral nutrition after parenteral nutrition. Combined use of the different formulas was observed in almost all hospitalized patients receiving enteral nutrition. In total, 61.5% of patients received triple therapy with Nutrison Fibre, Fresubin Diabetes, and Supportan. Number of defined daily doses (total dose consumed/defined daily dose, also called DDDs) of formulas in descending order were as follows: Nutrison Fibre, Fresubin Energy Fibre, Fresubin Diabetes > Supportan > Peptison, Ensure > Vivonex, Fresubin. The ratio of the cumulative DDDs for the three types of enteral nutrition was 35:2.8:1 (total protein type to short peptide type to amino acid type). Off-label use of Fresubin Diabetes was also observed, with most of this formula being prescribed for patients with stress hyperglycemia. Only 2.1% of cancer patients received Supportan. There were 35 cases of near misses in dispensing look-alike or sound-alike enteral nutrition formulas, and one adverse drug reaction in an elderly malnourished patient who did not receive vitamin K1-enriched enteral nutrition during treatment with cefoperazone. After 4 months of the trial intervention, off-label use of Fresubin Diabetes was no longer endorsed by the Drug and Therapeutics Committee for nondiabetic patients, and the proportion of this formula prescribed for patients with stress hyperglycemia decreased by 20%, with a 10-fold increase in the amount of Supportan prescribed for cancer patients. Near misses in dispensing look-alike or sound-alike enteral nutrition were successfully abolished, and no severe coagulation disorders occurred after prophylactic administration of vitamin K1-enriched enteral nutrition in elderly malnourished patients receiving cefoperazone. Conclusion This utilization study indicates that continuous quality improvement is necessary and that a Drug and Therapeutics Committee can play an important role in promoting rational and safe use of enteral nutrition. Appropriateness of this therapy still needs to be improved, especially in addressing the issues of non-evidence-based combined use of multiple enteral nutrition formulas, the relatively high rate of concomitant use of enteral and parenteral nutrition, off-label use of diabetes-specific Fresubin Diabetes, insufficient use of Supportan in cancer patients, and unnecessary use of Supportan in intensive care patients not suffering from cancer.

Adverse events associated with parenteral nutrition support therapy: A pharmacovigilance study

Prescribing Practice and Evaluation of Appropriateness of Enteral Nutrition in a University Teaching Hospital

ASPEN survey of parenteral nutrition access issues: How the system fails the patient

The Association Between Parenteral Nutrition and Pancreatic Injury in Adult Patients: a Retrospective Observational Study

Disproportionality Analysis of Nusinersen in the Food and Drug Administration Adverse Event Reporting System: A Real-World Postmarketing Pharmacovigilance Assessment

The real-world analysis of adverse events with teduglutide: a pharmacovigilance study based on the FAERS database

Peripheral parenteral nutrition: A retrospective observational study to evaluate utility and complications

Adverse events associated with Atogepant: a faers-based pharmacovigilance analysis

Pathogenesis and Treatment of Parenteral Nutrition-Associated Liver Disease

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?

A real-world study of antifibrotic drugs-related adverse events based on the United States food and drug administration adverse event reporting system and VigiAccess databases

The prevalence of parenteral nutrition-associated liver disease and its risk factors in elderly people after gastrointestinal operation

Safety and quality of parenteral nutrition: Areas for improvement and future perspectives

Parenteral nutrition-associated liver injury: clinical relevance and mechanistic insights

Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database

Delayed immune-related adverse events profile associated with immune checkpoint inhibitors: a real-world analysis

Enteral nutrition: An underappreciated source of patient safety events

Disproportionality Analysis of Nusinersen in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment

Refeeding syndrome in adults receiving total parenteral nutrition: An audit of practice at a tertiary UK centre

Proteome Characteristics of Liver Tissue from Patients with Parenteral Nutrition-Associated Liver Disease

A Real-World Disproportionality Analysis of Tirzepatide-Related Adverse Events Based on the FDA Adverse Event Reporting System (FAERS) Database